IL133305A0 - Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome - Google Patents

Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome

Info

Publication number
IL133305A0
IL133305A0 IL13330598A IL13330598A IL133305A0 IL 133305 A0 IL133305 A0 IL 133305A0 IL 13330598 A IL13330598 A IL 13330598A IL 13330598 A IL13330598 A IL 13330598A IL 133305 A0 IL133305 A0 IL 133305A0
Authority
IL
Israel
Prior art keywords
protein inhibitor
treating protein
binding interruptor
inhibitor syndrome
exogenous protein
Prior art date
Application number
IL13330598A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL133305A0 publication Critical patent/IL133305A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13330598A 1997-06-20 1998-06-19 Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome IL133305A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (1)

Publication Number Publication Date
IL133305A0 true IL133305A0 (en) 2001-04-30

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13330598A IL133305A0 (en) 1997-06-20 1998-06-19 Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome

Country Status (25)

Country Link
US (1) US20020119151A1 (de)
EP (1) EP1034001B1 (de)
JP (1) JP2002504910A (de)
KR (1) KR100567998B1 (de)
CN (2) CN1261285A (de)
AT (1) ATE272408T1 (de)
AU (1) AU733062B2 (de)
BG (1) BG64436B1 (de)
BR (1) BR9810755A (de)
CA (1) CA2294138A1 (de)
CZ (1) CZ295805B6 (de)
DE (1) DE69825473T2 (de)
EA (1) EA002512B1 (de)
EE (1) EE9900587A (de)
ES (1) ES2226152T3 (de)
HK (1) HK1031825A1 (de)
HU (1) HUP0002048A3 (de)
IL (1) IL133305A0 (de)
IS (1) IS2097B (de)
NO (1) NO996274L (de)
NZ (1) NZ502051A (de)
PT (1) PT1034001E (de)
SK (1) SK285962B6 (de)
TR (1) TR199903141T2 (de)
WO (1) WO1998058672A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011021A3 (cs) * 1998-09-21 2001-10-17 Genetics Institute, Inc. Způsoby tlumení imunitní odpovědi na terapeutické proteiny
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
CN1835976B (zh) * 2003-06-13 2012-06-13 比奥根艾迪克Ma公司 无糖基抗-cd154(cd40配体)抗体及其用途
NZ544486A (en) * 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
EP1682178B8 (de) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung von krebs mit expression des cd40-antigens
EP1791563A4 (de) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154-antikörper
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln

Also Published As

Publication number Publication date
NZ502051A (en) 2001-04-27
IS2097B (is) 2006-04-12
PT1034001E (pt) 2004-12-31
AU733062B2 (en) 2001-05-03
WO1998058672A1 (en) 1998-12-30
KR20010013964A (ko) 2001-02-26
AU8153698A (en) 1999-01-04
SK180399A3 (en) 2000-06-12
HK1031825A1 (en) 2001-06-29
HUP0002048A3 (en) 2002-09-30
KR100567998B1 (ko) 2006-04-07
CZ458899A3 (cs) 2000-04-12
NO996274L (no) 2000-02-18
EA200000059A1 (ru) 2000-08-28
DE69825473D1 (de) 2004-09-09
DE69825473T2 (de) 2005-08-04
NO996274D0 (no) 1999-12-17
IS5274A (is) 1999-11-26
ES2226152T3 (es) 2005-03-16
EE9900587A (et) 2000-08-15
JP2002504910A (ja) 2002-02-12
CN1261285A (zh) 2000-07-26
SK285962B6 (sk) 2007-12-06
CZ295805B6 (cs) 2005-11-16
EP1034001B1 (de) 2004-08-04
EA002512B1 (ru) 2002-06-27
ATE272408T1 (de) 2004-08-15
HUP0002048A2 (hu) 2000-10-28
US20020119151A1 (en) 2002-08-29
BG64436B1 (en) 2005-02-28
CN1651071A (zh) 2005-08-10
BR9810755A (pt) 2000-08-15
TR199903141T2 (xx) 2000-09-21
EP1034001A1 (de) 2000-09-13
BG104092A (en) 2000-10-31
CA2294138A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
IL133305A0 (en) Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome
UA66767C2 (uk) Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
AU2002360592A1 (en) Inhibitors of hepatitis c virus
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
EP1181585A4 (de) Breitbandiges polarisationsteiler,-mischer,-isolator und -regler
AU2001275228A1 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
UA72909C2 (en) Cinnamide derivatives useful in the treatment of inflammatory and immune diseases, a composition containing such derivatives and a method for the preparation of cinnamide derivatives
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
AU4726797A (en) Prophylactic/remedial agent
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
WO1998018818A3 (en) Hepatitis b inhibitors
EP0331803A3 (de) Medicament zum Verhindern oder zur Behandlung von Migräne durch Verwendung eines Ace-Inhibitors
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
IL114808A0 (en) Combination therapy for hiv
WO2004017902A3 (en) Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
MX9704579A (es) Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.